APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lung Cancer Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lung Cancer Treatment Drugs Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchLung Cancer Treatment Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Cancer Treatment Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Lung Cancer Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Cancer Treatment Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Cancer Treatment Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Lung Cancer Treatment Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lung Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lung Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lung Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lung Cancer Treatment Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lung Cancer Treatment Drugs market include Sanofi-Aventis, Roche, Eli Lilly and Company, Pfizer, GlaxoSmithKline and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lung Cancer Treatment Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lung Cancer Treatment Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lung Cancer Treatment Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lung Cancer Treatment Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Lung Cancer Treatment Drugs Segment by Company

Sanofi-Aventis

Roche

Eli Lilly and Company

Pfizer

GlaxoSmithKline

AstraZeneca

Lung Cancer Treatment Drugs Segment by Type

Chemotherapy

Pipeline Drugs

Targeted Therapies

Lung Cancer Treatment Drugs Segment by Application

Diagnostic Centers

Hospitals

Research Institutes

Others

Lung Cancer Treatment Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Lung Cancer Treatment Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Lung Cancer Treatment Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lung Cancer Treatment Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Lung Cancer Treatment Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lung Cancer Treatment Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lung Cancer Treatment Drugs industry.

Chapter 3: Detailed analysis of Lung Cancer Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Lung Cancer Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Lung Cancer Treatment Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lung Cancer Treatment Drugs Industry Trends Table 2. Lung Cancer Treatment Drugs Industry Drivers Table 3. Lung Cancer Treatment Drugs Industry Opportunities and Challenges Table 4. Lung Cancer Treatment Drugs Industry Restraints Table 5. Global Lung Cancer Treatment Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lung Cancer Treatment Drugs Revenue Share by Company (2021-2026) Table 7. Global Lung Cancer Treatment Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Lung Cancer Treatment Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Lung Cancer Treatment Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Lung Cancer Treatment Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Lung Cancer Treatment Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Lung Cancer Treatment Drugs Company, Product Type & Application Table 13. Global Lung Cancer Treatment Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Lung Cancer Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Chemotherapy Table 18. Significant Companies of Pipeline Drugs Table 19. Significant Companies of Targeted Therapies Table 20. Global Lung Cancer Treatment Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Lung Cancer Treatment Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Lung Cancer Treatment Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Lung Cancer Treatment Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Lung Cancer Treatment Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Lung Cancer Treatment Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Lung Cancer Treatment Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Lung Cancer Treatment Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Lung Cancer Treatment Drugs Sales Value Share by Type (2021-2026) Table 29. Global Lung Cancer Treatment Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Diagnostic Centers Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Research Institutes Table 33. Significant Companies of Others Table 34. Global Lung Cancer Treatment Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Lung Cancer Treatment Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Lung Cancer Treatment Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Lung Cancer Treatment Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Lung Cancer Treatment Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Lung Cancer Treatment Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Lung Cancer Treatment Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Lung Cancer Treatment Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Lung Cancer Treatment Drugs Sales Value Share by Application (2021-2026) Table 43. Global Lung Cancer Treatment Drugs Sales Value Share by Application (2027-2032) Table 44. Global Lung Cancer Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Lung Cancer Treatment Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Lung Cancer Treatment Drugs Sales Market Share by Region (2021-2026) Table 47. Global Lung Cancer Treatment Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Lung Cancer Treatment Drugs Sales Market Share by Region (2027-2032) Table 49. Global Lung Cancer Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Lung Cancer Treatment Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Lung Cancer Treatment Drugs Sales Value Share by Region (2021-2026) Table 52. Global Lung Cancer Treatment Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Lung Cancer Treatment Drugs Sales Value Share by Region (2027-2032) Table 54. Global Lung Cancer Treatment Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Lung Cancer Treatment Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Lung Cancer Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Lung Cancer Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Lung Cancer Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Lung Cancer Treatment Drugs Sales Market Share by Country (2021-2026) Table 60. Global Lung Cancer Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Lung Cancer Treatment Drugs Sales Market Share by Country (2027-2032) Table 62. Global Lung Cancer Treatment Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Lung Cancer Treatment Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Lung Cancer Treatment Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Lung Cancer Treatment Drugs Sales Value Market Share by Country (2027-2032) Table 66. Sanofi-Aventis Company Information Table 67. Sanofi-Aventis Business Overview Table 68. Sanofi-Aventis Lung Cancer Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Sanofi-Aventis Lung Cancer Treatment Drugs Product Portfolio Table 70. Sanofi-Aventis Recent Development Table 71. Roche Company Information Table 72. Roche Business Overview Table 73. Roche Lung Cancer Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Roche Lung Cancer Treatment Drugs Product Portfolio Table 75. Roche Recent Development Table 76. Eli Lilly and Company Company Information Table 77. Eli Lilly and Company Business Overview Table 78. Eli Lilly and Company Lung Cancer Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Eli Lilly and Company Lung Cancer Treatment Drugs Product Portfolio Table 80. Eli Lilly and Company Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Lung Cancer Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Pfizer Lung Cancer Treatment Drugs Product Portfolio Table 85. Pfizer Recent Development Table 86. GlaxoSmithKline Company Information Table 87. GlaxoSmithKline Business Overview Table 88. GlaxoSmithKline Lung Cancer Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline Lung Cancer Treatment Drugs Product Portfolio Table 90. GlaxoSmithKline Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Lung Cancer Treatment Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Lung Cancer Treatment Drugs Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. Lung Cancer Treatment Drugs Distributors List Table 99. Lung Cancer Treatment Drugs Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Lung Cancer Treatment Drugs Product Image Figure 2. Global Lung Cancer Treatment Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Cancer Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Lung Cancer Treatment Drugs Sales (2021-2032) & (K Units) Figure 5. Global Lung Cancer Treatment Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Lung Cancer Treatment Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Chemotherapy Image Figure 10. Pipeline Drugs Image Figure 11. Targeted Therapies Image Figure 12. Global Lung Cancer Treatment Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Lung Cancer Treatment Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Lung Cancer Treatment Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Lung Cancer Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Lung Cancer Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Lung Cancer Treatment Drugs Sales Value Share by Type (2021-2032) Figure 18. Diagnostic Centers Image Figure 19. Hospitals Image Figure 20. Research Institutes Image Figure 21. Others Image Figure 22. Global Lung Cancer Treatment Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Lung Cancer Treatment Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Lung Cancer Treatment Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Lung Cancer Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Lung Cancer Treatment Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Lung Cancer Treatment Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Lung Cancer Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Lung Cancer Treatment Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Lung Cancer Treatment Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Lung Cancer Treatment Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Lung Cancer Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Lung Cancer Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Lung Cancer Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Lung Cancer Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Lung Cancer Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Lung Cancer Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Lung Cancer Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Lung Cancer Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Lung Cancer Treatment Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Lung Cancer Treatment Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Lung Cancer Treatment Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Lung Cancer Treatment Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Pipeline Drugs
  • Targeted Therapies
Applications
  • Diagnostic Centers
  • Hospitals
  • Research Institutes
  • Others
Companies covered
  • Sanofi-Aventis
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Lung Cancer Treatment Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Lung Cancer Treatment Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Lung Cancer Treatment Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Lung Cancer Treatment Drugs Market Dynamics
  1. 2.1 Lung Cancer Treatment Drugs Industry Trends
  2. 2.2 Lung Cancer Treatment Drugs Industry Drivers
  3. 2.3 Lung Cancer Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 Lung Cancer Treatment Drugs Industry Restraints
3 Lung Cancer Treatment Drugs Market by Company
  1. 3.1 Global Lung Cancer Treatment Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Lung Cancer Treatment Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Lung Cancer Treatment Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Lung Cancer Treatment Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Lung Cancer Treatment Drugs Company Ranking (2024-2026)
  6. 3.6 Global Lung Cancer Treatment Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Lung Cancer Treatment Drugs Company Product Type and Application
  8. 3.8 Global Lung Cancer Treatment Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Lung Cancer Treatment Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Lung Cancer Treatment Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Lung Cancer Treatment Drugs Market by Type
  1. 4.1 Lung Cancer Treatment Drugs Type Introduction
  2. 4.1.1 Chemotherapy
  3. 4.1.2 Pipeline Drugs
  4. 4.1.3 Targeted Therapies
  5. 4.2 Global Lung Cancer Treatment Drugs Sales Volume by Type
  6. 4.2.1 Global Lung Cancer Treatment Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Lung Cancer Treatment Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Lung Cancer Treatment Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Lung Cancer Treatment Drugs Sales Value by Type
  10. 4.3.1 Global Lung Cancer Treatment Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Lung Cancer Treatment Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Lung Cancer Treatment Drugs Sales Value Share by Type (2021-2032)
5 Lung Cancer Treatment Drugs Market by Application
  1. 5.1 Lung Cancer Treatment Drugs Application Introduction
  2. 5.1.1 Diagnostic Centers
  3. 5.1.2 Hospitals
  4. 5.1.3 Research Institutes
  5. 5.1.4 Others
  6. 5.2 Global Lung Cancer Treatment Drugs Sales Volume by Application
  7. 5.2.1 Global Lung Cancer Treatment Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Lung Cancer Treatment Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Lung Cancer Treatment Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Lung Cancer Treatment Drugs Sales Value by Application
  11. 5.3.1 Global Lung Cancer Treatment Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Lung Cancer Treatment Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Lung Cancer Treatment Drugs Sales Value Share by Application (2021-2032)
6 Lung Cancer Treatment Drugs Regional Sales and Value Analysis
  1. 6.1 Global Lung Cancer Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lung Cancer Treatment Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Lung Cancer Treatment Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Lung Cancer Treatment Drugs Sales by Region (2027-2032)
  5. 6.3 Global Lung Cancer Treatment Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Lung Cancer Treatment Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Lung Cancer Treatment Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Lung Cancer Treatment Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Lung Cancer Treatment Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Lung Cancer Treatment Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Lung Cancer Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Lung Cancer Treatment Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Lung Cancer Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Lung Cancer Treatment Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Lung Cancer Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Lung Cancer Treatment Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Lung Cancer Treatment Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Lung Cancer Treatment Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Lung Cancer Treatment Drugs Sales Value Share by Country, 2025 VS 2032
7 Lung Cancer Treatment Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Lung Cancer Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lung Cancer Treatment Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Lung Cancer Treatment Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Lung Cancer Treatment Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Lung Cancer Treatment Drugs Sales by Country (2027-2032)
  6. 7.4 Global Lung Cancer Treatment Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Lung Cancer Treatment Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Lung Cancer Treatment Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Lung Cancer Treatment Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Lung Cancer Treatment Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Lung Cancer Treatment Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi-Aventis
  2. 8.1.1 Sanofi-Aventis Company Information
  3. 8.1.2 Sanofi-Aventis Business Overview
  4. 8.1.3 Sanofi-Aventis Lung Cancer Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi-Aventis Lung Cancer Treatment Drugs Product Portfolio
  6. 8.1.5 Sanofi-Aventis Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Lung Cancer Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Roche Lung Cancer Treatment Drugs Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company Lung Cancer Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company Lung Cancer Treatment Drugs Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Lung Cancer Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Lung Cancer Treatment Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Lung Cancer Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Lung Cancer Treatment Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Lung Cancer Treatment Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Lung Cancer Treatment Drugs Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lung Cancer Treatment Drugs Value Chain Analysis
  2. 9.1.1 Lung Cancer Treatment Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lung Cancer Treatment Drugs Sales Mode & Process
  6. 9.2 Lung Cancer Treatment Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lung Cancer Treatment Drugs Distributors
  9. 9.2.3 Lung Cancer Treatment Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst